Avastin licence extended in metastatic breast cancer

Bevacizumab is also licensed for colorectal, lung and renal cancer
Bevacizumab is also licensed for colorectal, lung and renal cancer
The licensed use of bevacizumab (Avastin) for the treatment of metastatic breast cancer has been broadened to include use in combination with capecitabine when taxanes or anthracyclines are not appropriate. Patients who have received taxane and anthracycline-containing regimens should not receive bevacizumab in combination with capecitabine.

Use of bevacizumab with capecitabine was evaluated in the multicentre, placebo-controlled, phase 3 RIBBON-1 study in patients with HER2-negative metastatic or locally recurrent breast cancer. Patients (n=1237) were randomised to receive chemotherapy plus bevacizumab or chemotherapy plus placebo every 3 weeks. Chemotherapy options included capecitabine, a taxane and anthracycline-based agents.

For statistical analysis, patients were divided into 2 cohorts defined by chemotherapy received. The primary endpoint, median progression-free survival, was longer for capecitabine plus bevacizumab than for capecitabine plus placebo: 8.6 months vs 5.7 months, with a hazard ratio of 0.69 (95% CI 0.56-0.84; p<0.001).

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Drug shortages - live tracker

Drug shortages - live tracker

Removed: Xepin.
Use our constantly updated shortages...

Vaping still safer than smoking, say health bosses after report of severe lung injury
Free online vestibular rehabilitation tool 'highly effective' for vertigo symptoms

Free online vestibular rehabilitation tool 'highly effective' for vertigo symptoms

GPs should consider online vestibular rehabilitation...

Thiazides better than ACE inhibitors as first-line antihypertensives, large-scale analysis suggests